Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis.

"Conflicts of interest HB and JPT are employees at LEO Pharma. MB, SBR and HHJ are employees of EY Economics Denmark, which is a paid vendor of LEO Pharma. MA has been a principal/chief investigator for clinical trials and/or served as an advisor for Elly Lilly, LEO Pharma, Pfizer, AbbVie, Regeneron and Sanofi. RA has received grants/research contracts from AbbVie and Novartis and served as a consultant and received honoraria from AbbVie, Galderma, LEO Pharma, Novartis, Pfizer and Sanofi-Genzyme. JPT has received grants from The Leo Foundation, The Novo Nordisk Foundation, The Lundbeck Foundation and grants from Savværksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat, during the conduct of the study. Outside of this study, JPT has served as an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, and served as a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron, and Sanofi-Genzyme."

"The author(s) disclosed receipt of the following financial support for the research and publication of this article: This work was supported by LEO Pharma (grant number is not applicable)."